Published in Biotech Business Week, July 11th, 2005
The randomized, double-blind, placebo-controlled, single-dose study will evaluate the clinical effects of IoGen in about 175 women.
Patients will receive one 6.0 mg tablet of IoGen or placebo daily for 6 months. The primary objective of the study is the evaluation of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.